Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members.

Prodigiosin and obatoclax, members of the prodiginines family, are small molecules with anti-cancer properties that are currently under preclinical and clinical trials. The molecular target(s) of these agents, however, is an open question. Combining experimental and computational techniques we find...

Full description

Bibliographic Details
Main Authors: Ali Hosseini, Margarita Espona-Fiedler, Vanessa Soto-Cerrato, Roberto Quesada, Ricardo Pérez-Tomás, Victor Guallar
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3583838?pdf=render
id doaj-c3ff65cb228c4be587d5f0ab79cad5b9
record_format Article
spelling doaj-c3ff65cb228c4be587d5f0ab79cad5b92020-11-25T02:32:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0182e5756210.1371/journal.pone.0057562Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members.Ali HosseiniMargarita Espona-FiedlerVanessa Soto-CerratoRoberto QuesadaRicardo Pérez-TomásVictor GuallarProdigiosin and obatoclax, members of the prodiginines family, are small molecules with anti-cancer properties that are currently under preclinical and clinical trials. The molecular target(s) of these agents, however, is an open question. Combining experimental and computational techniques we find that prodigiosin binds to the BH3 domain in some BCL-2 protein families, which play an important role in the apoptotic programmed cell death. In particular, our results indicate a large affinity of prodigiosin for MCL-1, an anti-apoptotic member of the BCL-2 family. In melanoma cells, we demonstrate that prodigiosin activates the mitochondrial apoptotic pathway by disrupting MCL-1/BAK complexes. Computer simulations with the PELE software allow the description of the induced fit process, obtaining a detailed atomic view of the molecular interactions. These results provide new data to understand the mechanism of action of these molecules, and assist in the development of more specific inhibitors of anti-apoptotic BCL-2 proteins.http://europepmc.org/articles/PMC3583838?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Ali Hosseini
Margarita Espona-Fiedler
Vanessa Soto-Cerrato
Roberto Quesada
Ricardo Pérez-Tomás
Victor Guallar
spellingShingle Ali Hosseini
Margarita Espona-Fiedler
Vanessa Soto-Cerrato
Roberto Quesada
Ricardo Pérez-Tomás
Victor Guallar
Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members.
PLoS ONE
author_facet Ali Hosseini
Margarita Espona-Fiedler
Vanessa Soto-Cerrato
Roberto Quesada
Ricardo Pérez-Tomás
Victor Guallar
author_sort Ali Hosseini
title Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members.
title_short Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members.
title_full Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members.
title_fullStr Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members.
title_full_unstemmed Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members.
title_sort molecular interactions of prodiginines with the bh3 domain of anti-apoptotic bcl-2 family members.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Prodigiosin and obatoclax, members of the prodiginines family, are small molecules with anti-cancer properties that are currently under preclinical and clinical trials. The molecular target(s) of these agents, however, is an open question. Combining experimental and computational techniques we find that prodigiosin binds to the BH3 domain in some BCL-2 protein families, which play an important role in the apoptotic programmed cell death. In particular, our results indicate a large affinity of prodigiosin for MCL-1, an anti-apoptotic member of the BCL-2 family. In melanoma cells, we demonstrate that prodigiosin activates the mitochondrial apoptotic pathway by disrupting MCL-1/BAK complexes. Computer simulations with the PELE software allow the description of the induced fit process, obtaining a detailed atomic view of the molecular interactions. These results provide new data to understand the mechanism of action of these molecules, and assist in the development of more specific inhibitors of anti-apoptotic BCL-2 proteins.
url http://europepmc.org/articles/PMC3583838?pdf=render
work_keys_str_mv AT alihosseini molecularinteractionsofprodiginineswiththebh3domainofantiapoptoticbcl2familymembers
AT margaritaesponafiedler molecularinteractionsofprodiginineswiththebh3domainofantiapoptoticbcl2familymembers
AT vanessasotocerrato molecularinteractionsofprodiginineswiththebh3domainofantiapoptoticbcl2familymembers
AT robertoquesada molecularinteractionsofprodiginineswiththebh3domainofantiapoptoticbcl2familymembers
AT ricardopereztomas molecularinteractionsofprodiginineswiththebh3domainofantiapoptoticbcl2familymembers
AT victorguallar molecularinteractionsofprodiginineswiththebh3domainofantiapoptoticbcl2familymembers
_version_ 1724821469053059072